Rainbow Coral Corp (RBCC) 0.5000 $RBCC
RBCC Ally n3D Inks Major Global Partnership Deal for Bioprinting Technology
Business Wire - Wed Oct 07, 4:00AM CDT
Rainbow Coral Corp. (OTCBB:RBCC) partner Nano3D Biosciences (n3D) has signed a major worldwide agreement with leading biotech supplier Greiner Bio-One, continuing the innovative company's steady march to the marketplace.
RBCC's Inclusionary Addiction Therapy Pricing Offers Hope to Those Shut Out from Help
Business Wire - Mon Oct 05, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) has won praise for its recent announcement that it will begin competitively pricing its addiction therapy programs, setting a new standard in affordability.
RBCC: Talks with Potential Canadian Joint Venture Partners Exceed Expectations
Business Wire - Thu Oct 01, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) reports recent talks with possible joint venture partners were quite productive and the company has high hopes it can work out agreements with several prospects as it nears its much anticipated Canadian rollout.
RBCC to Make Addiction Therapy Affordable for Everyone
Business Wire - Tue Sep 29, 4:00AM CDT
Rainbow Coral Corp. (OTCBB:RBCC) will now competitively price its groundbreaking addiction treatment services to lead the way in affordability. The goal of the new pricing policy is to ensure that those who need help have access to progressive, reasonably priced solutions that before may have been beyond their means.
RBCC Actively Seeking Joint Venture Partners for Upcoming Canadian Rollouts
Business Wire - Wed Sep 23, 7:22AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) has been aggressively pursuing potential partners for joint venture opportunities related to the company's proposed Canadian personalized medicine and addiction treatment rollouts. RBCC is seeking to meet with interested parties, including companies as well as medical, governmental and ethnic groups, to discuss collaboration.
RBCC: World's Largest Stem Cell Collection Could Lead to New Medical Advances
Business Wire - Mon Sep 21, 4:00AM CDT
California has opened a new human stem cell collection that officials say will enable new disease investigations and could result in exciting drug discoveries. Biotech innovator Rainbow Coral Corp. (OTCBB: RBCC) praised the opening and looks forward to the outcome of the future stem cell therapy studies, leaving open the possibility of taking part in some of them.
RBCC Partner n3D's Innovative Toxicity Test Highlighted in Major Scientific Journal
Business Wire - Wed Sep 16, 4:00AM CDT
Rainbow Coral Corp. (OTCBB:RBCC) partner n3D has just had an important manuscript about 3D bioprinting and cell culture screenings published in the journal Scientific Reports, a Nature publication.
RBCC: Federal Initiative Could Further Boost Personalized Medicine in U.S.
Business Wire - Wed Sep 09, 4:00AM CDT
Rainbow Coral Corp. (OTCBB:RBCC) is weighing options and considering future moves now that the Obama Administration has begun soliciting the medical community and the public for ideas on personalizing medical treatments to meet individual patient needs. The search for suggestions is the first step of the president's Precision Medicine Initiative (PMI), proposed last January - a wide-ranging $215 million federal program that could spell great opportunity for companies engaged in developing and distributing personalized medicine solutions, such as RBCC.
RBCC: New Jersey Initiates New Law Boosting Medication Assisted Treatment
Business Wire - Thu Sep 03, 4:00AM CDT
Rainbow Coral Corp. (OTCBB:RBCC) expects legislation in New Jersey giving additional credence and importance to Medication Assisted Treatment (MAT) programs to have a positive effect on patients and on distribution of Naltrexone, a drug MATs use to fight opioid addiction.
RBCC Partner n3D Signs Research Sponsorship Agreement with Prominent Medical School
Business Wire - Mon Aug 24, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) partner Nano3D Biosciences (n3D) has just inked an important sponsored research agreement with the prestigious University of Texas Health Science Center at Houston (UTHealth) Department of Obstetrics, Gynecology, and Reproductive Sciences. The agreement covers studies on personalized pre-term labor management and treatments.
RBCC Eagerly Following White House Plans to Counter Heroin/Painkiller Abuse
Business Wire - Wed Aug 19, 4:00AM CDT
Rainbow Coral Corp. (RBCC) has taken note of the Obama Administration's recent announcement of a new strategy to cut heroin and opiate use in several East Coast states. The company stands ready to assist and support Federal Medication Assisted Treatment (MAT) programs utilizing Naltrexone, an important prescription drug used in treatment of heroin and opiate addiction.
Naltrexone for Opioid Addiction Spotlighted in Vermont Treatment Grant
Business Wire - Thu Aug 13, 4:00AM CDT
Rainbow Coral Corp. (RBCC) hailed Vermont's recent winning of a $3 million grant to aid opioid addiction treatment in the Green Mountain State, and pledged to provide support for similar Medication Assisted Treatment (MAT) programs throughout the country utilizing Naltrexone.
RBCC Partner n3D To Start Global Distribution of 3D Bioprinting Technology
Business Wire - Tue Aug 11, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) joint venture partner Nano3D Biosciences (n3D) has signed a major worldwide distribution agreement with Reprocell for its revolutionary three-dimensional bioprinting product lines. Under the pact, Reprocell will market and sell n3D's BioAssembler and Magnetic 3D Bioprinting products to academic and governmental-institute life science researchers as well as to the pharmaceutical and biotech industries.
RBCC: U.S. Alcohol Abuse Costs Go Beyond Dollars, Shows Need for Concrete Answers
Business Wire - Tue Jul 28, 4:00AM CDT
Americans are paying a high price when it comes to alcohol abuse in terms of health costs, lost productivity and law enforcement activities according to study after study. Rainbow Coral Corp. (RBCC) has been actively looking for solutions to this affliction, seeking out partners to distribute Naltrexone, a drug that impedes the cravings to drink.
RBCC: North American Substance Abuse Stats Show Growing Need for Solution
Business Wire - Thu Jul 23, 4:00AM CDT
Substance abuse numbers from the United States and Canada demonstrate Naltrexone has strong growth potential, strengthening Rainbow Coral Corp.'s (RBCC) plans to aggressively pursue additional partners and distribution channels to get the anti-addiction drug into as many markets as possible.
RBCC Ready to Sign LOI with Canadian Medical Group
Business Wire - Tue Jul 21, 4:00AM CDT
Biotech company Rainbow Coral Corp. (RBCC) is discussing a letter of intent with a Canadian medical services group that treats alcohol addiction utilizing Naltrexone.
RBCC: Naltrexone's Growing List of Applications and Uses Expands Its Market Potential
Business Wire - Thu Jul 16, 4:00AM CDT
Biotech company Rainbow Coral Corp. (RBCC) reports its flagship drug Naltrexone continues to gain widespread acceptance in the medical world as researchers discover more and more practical and beneficial uses for it. As Naltrexone's acceptance and usage spreads, RBCC expects to enjoy greater revenues from the drug.
RBCC Nears Major Agreement to Distribute Naltrexone in Canada
Business Wire - Thu Jul 09, 4:00AM CDT
Biotech company Rainbow Coral Corp. (RBCC) is drawing closer to a milestone agreement with a partner company to distribute Naltrexone - an important prescription drug used in treatment of alcohol and opiate addiction - in Canada. When reached and implemented, the agreement will open a crucial new revenue stream for RBCC as the FDA-approved drug's previous success has resulted in increased demand for effective new Naltrexone treatments from a wide spectrum of patients.
RBCC Explores New Pharmaceutical Compounding Opportunities in Booming Personalized Medicine Industry
Business Wire - Tue Jun 02, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB:RBCC) works to diversify its rapidly growing biotech business, the company is exploring new opportunities to provide innovative new products and services to the pharmaceutical compounding industry.
ABT: 41.89 (+0.73), BIIB: 269.16 (-10.72), VRX: 175.94 (+4.77)
RBCC Ally n3D Inks Major Global Partnership Deal for Bioprinting Technology
Business Wire - Wed Oct 07, 4:00AM CDT
Rainbow Coral Corp. (OTCBB:RBCC) partner Nano3D Biosciences (n3D) has signed a major worldwide agreement with leading biotech supplier Greiner Bio-One, continuing the innovative company's steady march to the marketplace.
RBCC's Inclusionary Addiction Therapy Pricing Offers Hope to Those Shut Out from Help
Business Wire - Mon Oct 05, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) has won praise for its recent announcement that it will begin competitively pricing its addiction therapy programs, setting a new standard in affordability.
RBCC: Talks with Potential Canadian Joint Venture Partners Exceed Expectations
Business Wire - Thu Oct 01, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) reports recent talks with possible joint venture partners were quite productive and the company has high hopes it can work out agreements with several prospects as it nears its much anticipated Canadian rollout.
RBCC to Make Addiction Therapy Affordable for Everyone
Business Wire - Tue Sep 29, 4:00AM CDT
Rainbow Coral Corp. (OTCBB:RBCC) will now competitively price its groundbreaking addiction treatment services to lead the way in affordability. The goal of the new pricing policy is to ensure that those who need help have access to progressive, reasonably priced solutions that before may have been beyond their means.
RBCC Actively Seeking Joint Venture Partners for Upcoming Canadian Rollouts
Business Wire - Wed Sep 23, 7:22AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) has been aggressively pursuing potential partners for joint venture opportunities related to the company's proposed Canadian personalized medicine and addiction treatment rollouts. RBCC is seeking to meet with interested parties, including companies as well as medical, governmental and ethnic groups, to discuss collaboration.
RBCC: World's Largest Stem Cell Collection Could Lead to New Medical Advances
Business Wire - Mon Sep 21, 4:00AM CDT
California has opened a new human stem cell collection that officials say will enable new disease investigations and could result in exciting drug discoveries. Biotech innovator Rainbow Coral Corp. (OTCBB: RBCC) praised the opening and looks forward to the outcome of the future stem cell therapy studies, leaving open the possibility of taking part in some of them.
RBCC Partner n3D's Innovative Toxicity Test Highlighted in Major Scientific Journal
Business Wire - Wed Sep 16, 4:00AM CDT
Rainbow Coral Corp. (OTCBB:RBCC) partner n3D has just had an important manuscript about 3D bioprinting and cell culture screenings published in the journal Scientific Reports, a Nature publication.
RBCC: Federal Initiative Could Further Boost Personalized Medicine in U.S.
Business Wire - Wed Sep 09, 4:00AM CDT
Rainbow Coral Corp. (OTCBB:RBCC) is weighing options and considering future moves now that the Obama Administration has begun soliciting the medical community and the public for ideas on personalizing medical treatments to meet individual patient needs. The search for suggestions is the first step of the president's Precision Medicine Initiative (PMI), proposed last January - a wide-ranging $215 million federal program that could spell great opportunity for companies engaged in developing and distributing personalized medicine solutions, such as RBCC.
RBCC: New Jersey Initiates New Law Boosting Medication Assisted Treatment
Business Wire - Thu Sep 03, 4:00AM CDT
Rainbow Coral Corp. (OTCBB:RBCC) expects legislation in New Jersey giving additional credence and importance to Medication Assisted Treatment (MAT) programs to have a positive effect on patients and on distribution of Naltrexone, a drug MATs use to fight opioid addiction.
RBCC Partner n3D Signs Research Sponsorship Agreement with Prominent Medical School
Business Wire - Mon Aug 24, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) partner Nano3D Biosciences (n3D) has just inked an important sponsored research agreement with the prestigious University of Texas Health Science Center at Houston (UTHealth) Department of Obstetrics, Gynecology, and Reproductive Sciences. The agreement covers studies on personalized pre-term labor management and treatments.
RBCC Eagerly Following White House Plans to Counter Heroin/Painkiller Abuse
Business Wire - Wed Aug 19, 4:00AM CDT
Rainbow Coral Corp. (RBCC) has taken note of the Obama Administration's recent announcement of a new strategy to cut heroin and opiate use in several East Coast states. The company stands ready to assist and support Federal Medication Assisted Treatment (MAT) programs utilizing Naltrexone, an important prescription drug used in treatment of heroin and opiate addiction.
Naltrexone for Opioid Addiction Spotlighted in Vermont Treatment Grant
Business Wire - Thu Aug 13, 4:00AM CDT
Rainbow Coral Corp. (RBCC) hailed Vermont's recent winning of a $3 million grant to aid opioid addiction treatment in the Green Mountain State, and pledged to provide support for similar Medication Assisted Treatment (MAT) programs throughout the country utilizing Naltrexone.
RBCC Partner n3D To Start Global Distribution of 3D Bioprinting Technology
Business Wire - Tue Aug 11, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) joint venture partner Nano3D Biosciences (n3D) has signed a major worldwide distribution agreement with Reprocell for its revolutionary three-dimensional bioprinting product lines. Under the pact, Reprocell will market and sell n3D's BioAssembler and Magnetic 3D Bioprinting products to academic and governmental-institute life science researchers as well as to the pharmaceutical and biotech industries.
RBCC: U.S. Alcohol Abuse Costs Go Beyond Dollars, Shows Need for Concrete Answers
Business Wire - Tue Jul 28, 4:00AM CDT
Americans are paying a high price when it comes to alcohol abuse in terms of health costs, lost productivity and law enforcement activities according to study after study. Rainbow Coral Corp. (RBCC) has been actively looking for solutions to this affliction, seeking out partners to distribute Naltrexone, a drug that impedes the cravings to drink.
RBCC: North American Substance Abuse Stats Show Growing Need for Solution
Business Wire - Thu Jul 23, 4:00AM CDT
Substance abuse numbers from the United States and Canada demonstrate Naltrexone has strong growth potential, strengthening Rainbow Coral Corp.'s (RBCC) plans to aggressively pursue additional partners and distribution channels to get the anti-addiction drug into as many markets as possible.
RBCC Ready to Sign LOI with Canadian Medical Group
Business Wire - Tue Jul 21, 4:00AM CDT
Biotech company Rainbow Coral Corp. (RBCC) is discussing a letter of intent with a Canadian medical services group that treats alcohol addiction utilizing Naltrexone.
RBCC: Naltrexone's Growing List of Applications and Uses Expands Its Market Potential
Business Wire - Thu Jul 16, 4:00AM CDT
Biotech company Rainbow Coral Corp. (RBCC) reports its flagship drug Naltrexone continues to gain widespread acceptance in the medical world as researchers discover more and more practical and beneficial uses for it. As Naltrexone's acceptance and usage spreads, RBCC expects to enjoy greater revenues from the drug.
RBCC Nears Major Agreement to Distribute Naltrexone in Canada
Business Wire - Thu Jul 09, 4:00AM CDT
Biotech company Rainbow Coral Corp. (RBCC) is drawing closer to a milestone agreement with a partner company to distribute Naltrexone - an important prescription drug used in treatment of alcohol and opiate addiction - in Canada. When reached and implemented, the agreement will open a crucial new revenue stream for RBCC as the FDA-approved drug's previous success has resulted in increased demand for effective new Naltrexone treatments from a wide spectrum of patients.
RBCC Explores New Pharmaceutical Compounding Opportunities in Booming Personalized Medicine Industry
Business Wire - Tue Jun 02, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB:RBCC) works to diversify its rapidly growing biotech business, the company is exploring new opportunities to provide innovative new products and services to the pharmaceutical compounding industry.
ABT: 41.89 (+0.73), BIIB: 269.16 (-10.72), VRX: 175.94 (+4.77)
